Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this trea...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Lancet Infect Dis
Huvudupphovsmän: Hakim, James G, Thompson, Jennifer, Kityo, Cissy, Hoppe, Anne, Kambugu, Andrew, van Oosterhout, Joep J, Lugemwa, Abbas, Siika, Abraham, Mwebaze, Raymond, Mweemba, Aggrey, Abongomera, George, Thomason, Margaret J, Easterbrook, Philippa, Mugyenyi, Peter, Walker, A Sarah, Paton, Nicholas I
Materialtyp: Artigo
Språk:Inglês
Publicerad: Elsevier Science ;, The Lancet Pub. Group 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739875/
https://ncbi.nlm.nih.gov/pubmed/29108797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(17)30630-8
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk